The STATs of cancer — new molecular targets come of age

Tumour cells acquire the ability to proliferate uncontrollably, resist apoptosis, sustain angiogenesis and evade immune surveillance. STAT proteins — especially STAT3 and STAT5 — regulate all of these processes and are persistently activated in a surprisingly large number of human cancers. Consequently, STAT proteins are emerging — unexpectedly — as ideal targets for cancer therapy.

[1]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[2]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[3]  R. Weinberg,et al.  The pathway to signal achievement , 1993, Nature.

[4]  D. Levy,et al.  Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. , 1993, Science.

[5]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[6]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[7]  J. Darnell,et al.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.

[8]  J. Darnell,et al.  Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver. , 1994, The Journal of biological chemistry.

[9]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[10]  R. Jove,et al.  Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. , 1995, Science.

[11]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[12]  B. Ponder,et al.  Molecular Genetics of Cancer , 1992, Nature Medicine.

[13]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[14]  J. Darnell,et al.  Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[16]  T. Kishimoto,et al.  Gp130 and the interleukin-6 family of cytokines. , 1997, Annual review of immunology.

[17]  J. Parsons,et al.  Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. , 1997, Current opinion in cell biology.

[18]  L. Hennighausen,et al.  Stat5a is mandatory for adult mammary gland development and lactogenesis. , 1997, Genes & development.

[19]  S. Akira,et al.  Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Jove,et al.  Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[21]  M. McMahon,et al.  Identification and Characterization of a Constitutively Active STAT5 Mutant That Promotes Cell Proliferation , 2022 .

[22]  Michael P. Brown,et al.  Stat5a and Stat5b Proteins Have Essential and Nonessential, or Redundant, Roles in Cytokine Responses , 1998, Cell.

[23]  J. Turkson,et al.  Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.

[24]  J. Darnell.  Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[25]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[26]  J. Darnell,et al.  Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.

[27]  J. Grandis,et al.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.

[28]  R. Jove,et al.  STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. , 1999, Current opinion in oncology.

[29]  Chi V. Dang,et al.  c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.

[30]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[31]  G. Prendergast,et al.  Mechanisms of apoptosis by c-Myc , 1999, Oncogene.

[32]  H. Lodish,et al.  Fetal Anemia and Apoptosis of Red Cell Progenitors in Stat5a−/−5b−/− Mice A Direct Role for Stat5 in Bcl-XL Induction , 1999, Cell.

[33]  T. Veikkola,et al.  VEGFs, receptors and angiogenesis. , 1999, Seminars in cancer biology.

[34]  S. Akira,et al.  Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.

[35]  Protein tyrosine kinase inhibitors as novel therapeutic agents. , 1999, Pharmacology & therapeutics.

[36]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[37]  M. Jaroszeski,et al.  Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. , 1999, Cancer research.

[38]  T. Naka,et al.  Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. , 1999, Trends in biochemical sciences.

[39]  D. Hilton,et al.  Negative regulation of the JAK/STAT pathway , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[40]  D. Hanahan,et al.  Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. , 1999, Cancer research.

[41]  S. Rane,et al.  IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled , 2000, Oncogene.

[42]  J. Grandis,et al.  STAT signaling in head and neck cancer , 2000, Oncogene.

[43]  S. Sukumar,et al.  Compromised HOXA5 function can limit p53 expression in human breast tumours , 2000, Nature.

[44]  N. Danial,et al.  JAK-STAT signaling activated by Abl oncogenes , 2000, Oncogene.

[45]  J. Darnell,et al.  The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.

[46]  T. Yeatman,et al.  Role of Src expression and activation in human cancer , 2000, Oncogene.

[47]  K. Shuai,et al.  Modulation of STAT signaling by STAT-interacting proteins , 2000, Oncogene.

[48]  M. Loh,et al.  Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. , 2000, Molecular cell.

[49]  D. Tweardy,et al.  Interleukin‐6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway , 2000, The Prostate.

[50]  Simon C Watkins,et al.  Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[51]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[52]  R. Kerbel,et al.  Oncogenes and angiogenesis: signaling three-dimensional tumor growth. , 2000, The journal of investigative dermatology. Symposium proceedings.

[53]  J. Gibbs.  Mechanism-based target identification and drug discovery in cancer research. , 2000, Science.

[54]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[55]  S. Akira.  Roles of STAT3 defined by tissue-specific gene targeting , 2000, Oncogene.

[56]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[57]  Mikhail Chernov,et al.  Regulation of c‐myc expression by IFN‐γ through Stat1‐dependent and ‐independent pathways , 2000 .

[58]  E. Andreu,et al.  Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XL , 2000, The Journal of experimental medicine.

[59]  J. Turkson,et al.  STAT proteins: novel molecular targets for cancer drug discovery , 2000, Oncogene.

[60]  J. Griffin,et al.  Bcr/Abl activates transcription of the Bcl-X gene through STAT5. , 2000, Blood.

[61]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[62]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[63]  T. Hirano,et al.  Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors , 2000, Oncogene.

[64]  Thomas S. Lin,et al.  STAT signaling in the pathogenesis and treatment of leukemias , 2000, Oncogene.

[65]  J. Turkson,et al.  Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling , 2000, Oncogene.

[66]  J. Griffin,et al.  STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. , 2000, Blood.

[67]  T. Veikkola,et al.  Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.

[68]  J. Darnell,et al.  Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[69]  J. Turkson,et al.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.

[70]  J. Ihle.  The Stat family in cytokine signaling. , 2001, Current opinion in cell biology.

[71]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[72]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[73]  T. Yeatman,et al.  Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[74]  B. Elliott,et al.  Co-operative Effect of c-Src Tyrosine Kinase and Stat3 in Activation of Hepatocyte Growth Factor Expression in Mammary Carcinoma Cells* , 2001, The Journal of Biological Chemistry.

[75]  J. Turkson,et al.  Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation* , 2001, The Journal of Biological Chemistry.

[76]  R. Jove,et al.  Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. , 2001, Cancer research.

[77]  B. Nelson,et al.  Stat5 and Sp1 Regulate Transcription of the Cyclin D2 Gene in Response to IL-21 , 2001, The Journal of Immunology.

[78]  J. Herman,et al.  SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity , 2001, Nature Genetics.

[79]  Hua Yu,et al.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells , 2001, Oncogene.

[80]  Hua Yu,et al.  Inhibition of Bcr–Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells , 2002, Oncogene.

[81]  J. Pow-Sang,et al.  Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. , 2002, Cancer research.

[82]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[83]  L. Ellis,et al.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.

[84]  M. Baccarani,et al.  Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. , 2002, Blood.

[85]  John K. Buolamwini,et al.  Novel Molecular Targets for Cancer Drug Discovery , 2002 .

[86]  N. Bazan,et al.  Phosphorylation of STAT-3 in Response to Basic Fibroblast Growth Factor Occurs through a Mechanism Involving Platelet-activating Factor, JAK-2, and Src in Human Umbilical Vein Endothelial Cells , 2002, The Journal of Biological Chemistry.

[87]  Drew M. Pardoll,et al.  Vaccines: Spinning molecular immunology into successful immunotherapy , 2002, Nature Reviews Immunology.

[88]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[89]  R. Jove,et al.  Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis , 2002, Oncogene.

[90]  J. Darnell.  Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.

[91]  D. Frank,et al.  The role of STATs in apoptosis. , 2002, Current molecular medicine.

[92]  R. DePinho,et al.  STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. , 2002, Immunity.

[93]  C. Meijer,et al.  Prostanoids Play a Major Role in the Primary Tumor-Induced Inhibition of Dendritic Cell Differentiation , 2002, The Journal of Immunology.

[94]  D. Levy,et al.  Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death , 2002, Oncogene.

[95]  B. Smith,et al.  A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. , 2002, Blood.

[96]  J. Grandis,et al.  STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. , 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[97]  D. Boger,et al.  Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[98]  G. Semenza.  Involvement of hypoxia-inducible factor 1 in human cancer. , 2002, Internal medicine.

[99]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[100]  William C Hahn,et al.  Rules for making human tumor cells. , 2002, The New England journal of medicine.

[101]  Qian Zhang,et al.  Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma1 , 2002, The Journal of Immunology.

[102]  Hua Yu,et al.  Roles of activated Src and Stat3 signaling in melanoma tumor cell growth , 2002, Oncogene.

[103]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[104]  M. Masuda,et al.  Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. , 2002, Cancer research.

[105]  J. Pow-Sang,et al.  Constitutive Activation of Stat 3 in Human Prostate Tumors and Cell Lines : Direct Inhibition of Stat 3 Signaling Induces Apoptosis of Prostate Cancer Cells 1 , 2002 .

[106]  Chia-Hung Chou,et al.  Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway , 2003, Oncogene.

[107]  J. S. Gutkind,et al.  Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. , 2003, Cancer research.

[108]  K. Sayama,et al.  Nuclear Translocation of Phosphorylated STAT3 Is Essential for Vascular Endothelial Growth Factor-induced Human Dermal Microvascular Endothelial Cell Migration and Tube Formation* , 2003, Journal of Biological Chemistry.

[109]  M. Bartoli,et al.  The FASEB Journal express article 10.1096/fj.02-1084fje. Published online June 17, 2003. VEGF differentially activates STAT3 in microvascular endothelial cells , 2022 .

[110]  G. Feldman,et al.  Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. , 2003, Blood.

[111]  J. Abbruzzese,et al.  Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis , 2003, Oncogene.

[112]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[113]  A. Yang,et al.  Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. , 2003, Cancer research.

[114]  J. Herman,et al.  SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. , 2003, Blood.

[115]  J. Turkson,et al.  Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells , 2003, Oncogene.

[116]  J. Grandis,et al.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[117]  E. Fikrig,et al.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[118]  D. Frank.  StAT signaling in cancer: insights into pathogenesis and treatment strategies. , 2003, Cancer treatment and research.

[119]  Shu-Wha Lin,et al.  SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia , 2003, Genes, chromosomes & cancer.

[120]  B. Cochran,et al.  Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells , 2003, BMC Cancer.

[121]  J. Turkson,et al.  Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. , 2003, Cancer research.

[122]  Hua Yu,et al.  A critical role for Stat3 signaling in immune tolerance. , 2003, Immunity.

[123]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[124]  D. Pardoll,et al.  Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.

[125]  J. Grandis,et al.  Src Kinases Mediate STAT Growth Pathways in Squamous Cell Carcinoma of the Head and Neck* , 2003, Journal of Biological Chemistry.

[126]  R. Jove,et al.  Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer , 2004, The Journal of Immunology.

[127]  J. Turkson,et al.  Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. , 2004, Molecular cancer therapeutics.

[128]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[129]  J. Darnell,et al.  Transcriptionally active Statl is required for the antiproliferative effects of both interferon a and interferon , 2005 .